CAMBRIDGE, MA—Mo Qatanani, the Chief Scientific Officer of Scholar Rock Holding Corp (NASDAQ:SRRK), executed a sale of 7,347 shares of common stock, according to a recent SEC filing. The shares were sold at an average price of $44.1972, totaling approximately $324,716. The transaction comes as the $4.19 billion market cap company trades near its 52-week high of $46.19, having delivered an impressive 395% return over the past six months. InvestingPro analysis indicates the stock is currently trading above its Fair Value.
This transaction was carried out to cover tax withholding obligations related to the vesting of restricted stock units (RSUs) on January 15, 2025. The sale was not a discretionary trade by Qatanani, but rather a mandated action under Scholar Rock’s equity incentive plans. Following this transaction, Qatanani retains ownership of 135,421 shares, which includes 36,158 shares of common stock and 99,263 RSUs. The company maintains strong liquidity with a current ratio of 3.88. For comprehensive insider trading analysis and 13 additional key insights, visit InvestingPro.
In other recent news, biopharmaceutical company Scholar Rock is advancing towards the commercialization of apitegromab, a potential treatment for spinal muscular atrophy (SMA). Regulatory applications are scheduled for submission in the first quarter of 2025, with a U.S. launch anticipated in the fourth quarter of the same year. The company’s strategic priorities for 2025 include the commercialization of apitegromab for SMA, expanding the potential benefits of apitegromab, and advancing the anti-myostatin program in cardiometabolic disorders.
Apitegromab has received Fast Track, Orphan Drug, and Rare Pediatric Disease designations from the FDA, as well as PRIME and Orphan Medicinal Product designations from the EMA for the treatment of SMA. Analysts from H.C. Wainwright, Truist Securities, and BMO Capital Markets have recently upgraded their price targets for Scholar Rock following significant developments in its drug trials.
Scholar Rock is also advancing its cardiometabolic program, with topline data from the Phase 2 EMBRAZE trial in obesity expected in the second quarter of 2025. Another candidate, SRK-439, is on track for an Investigational New Drug (IND) application filing in the third quarter of 2025 for obesity treatment. These recent developments highlight Scholar Rock’s consistent efforts to address unmet needs in the medical field.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.